AimVion is changing the game for autoimmune treatments!
8200 - Aarhus
Autoimmune diseases are life long diseases, affecting a large number of people at any age, gender, race. It takes many years and multiple specialists to correctly diagnose a patient, where most treatments are only reducing the symptoms and generally are very expensive. At the same time, many patients do not respond properly to existing treatments of autoimmune diseases.
AimVion aims to bring better treatments to the patients through advancing novel anti-inflammation technologies and devising new and affordable treatments against autoimmune diseases.
The company has been developing a library of peptides with immune modulating activities. A collection of peptides designed based on the discoveries and insights into the structure of new gene functions. AimVion’s research team have found a new gene that plays an important role in the regulation of the immune system, specially in autoimmune patients. They’ve then used this knowledge to design peptides that can modulate the immune system.
AimVion is set to develop new treatments for multiple autoimmune diseases up to clinical phase II through a combination of external funding and early partnering of its lead compound in carefully selected indications within its target product profiles.